David A. Siegel Inovio Pharmaceuticals, Inc. Transaction History

Two Sigma Advisers, LP

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.35 - $0.53 $36,435 - $55,173	104,100 Added 788.64%	117,300 $59,000
Q3 2023 Nov 14, 2023	SELL	$0.38 - $0.58 $176,168 - $268,888	-463,600 Reduced 97.23%	13,200 $5,000
Q2 2023 Aug 14, 2023	BUY	$0.39 - $0.94 $177,918 - $428,828	456,200 Added 2214.56%	476,800 $214,000
Q1 2023 May 15, 2023	SELL	$0.79 - $1.91 $1.02 Million - $2.47 Million	-1,290,600 Reduced 98.43%	20,600 $16,000
Q4 2022 Feb 14, 2023	SELL	$1.41 - $2.5 $1.34 Million - $2.38 Million	-950,200 Reduced 42.02%	1,311,200 $2.05 Million
Q3 2022 Nov 14, 2022	SELL	$1.66 - $2.79 $1.28 Million - $2.15 Million	-769,300 Reduced 25.38%	2,261,400 $3.9 Million
Q2 2022 Aug 15, 2022	BUY	$1.44 - $3.98 $4.12 Million - $11.4 Million	2,860,700 Added 1682.76%	3,030,700 $5.24 Million
Q1 2022 May 16, 2022	BUY	$2.97 - $5.2 $504,900 - $884,000	170,000 New	170,000 $610,000
Q2 2020 Aug 14, 2020	SELL	$7.14 - $31.69 $491,946 - $2.18 Million	-68,900 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$2.98 - $14.09 $62,282 - $294,481	20,900 Added 43.54%	68,900 $513,000
Q4 2019 Feb 14, 2020	BUY	$1.97 - $3.72 $25,019 - $47,244	12,700 Added 35.98%	48,000 $158,000
Q3 2019 Nov 14, 2019	BUY	$2.05 - $3.02 $33,312 - $49,075	16,250 Added 85.3%	35,300 $72,000
Q2 2019 Aug 14, 2019	BUY	$2.29 - $4.1 $43,624 - $78,105	19,050 New	19,050 $56,000
Q4 2018 Feb 14, 2019	SELL	$3.89 - $6.11 $41,234 - $64,766	-10,600 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$3.92 - $5.58 $41,552 - $59,148	10,600 New	10,600 $59,000

281K

Ticker INO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 249,400,000
Market Cap $476M
Description
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA se...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.